MA61866B1 - Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 - Google Patents
Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2Info
- Publication number
- MA61866B1 MA61866B1 MA61866A MA61866A MA61866B1 MA 61866 B1 MA61866 B1 MA 61866B1 MA 61866 A MA61866 A MA 61866A MA 61866 A MA61866 A MA 61866A MA 61866 B1 MA61866 B1 MA 61866B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- formula
- inhibitors
- diacylglyceride
- acyltransferase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
L'invention concerne des composés de formule I et des sels, esters et promédicaments pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de DGAT2. L'invention concerne également des procédés de fabrication de composés de formule I, des compositions pharmaceutiques comprenant les composés de formule I et des procédés d'utilisation de ces composés pour traiter la stéatose hépatique, la stéatohépatite non alcoolique (NASH), la fibrose, le diabète sucré de type 2, l'obésité, l'hyperlipidémie, l'hypercholestérolémie, l'athérosclérose, le déclin cognitif, la démence, les maladies cardiorénales telles que les maladies rénales chroniques et l'insuffisance cardiaque et des maladies et affections associées, comprenant l'administration d'un composé de formule I à un patient en ayant besoin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089068P | 2020-10-08 | 2020-10-08 | |
| PCT/US2021/053680 WO2022076495A1 (fr) | 2020-10-08 | 2021-10-06 | Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 |
| EP21802077.4A EP4225739B1 (fr) | 2020-10-08 | 2021-10-06 | Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA61866B1 true MA61866B1 (fr) | 2026-02-27 |
Family
ID=78500729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA61866A MA61866B1 (fr) | 2020-10-08 | 2021-10-06 | Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11976061B2 (fr) |
| EP (1) | EP4225739B1 (fr) |
| JP (1) | JP7604636B2 (fr) |
| KR (1) | KR20230084258A (fr) |
| CN (1) | CN116685577A (fr) |
| AR (1) | AR123700A1 (fr) |
| AU (1) | AU2021356589A1 (fr) |
| CA (1) | CA3195014A1 (fr) |
| CL (1) | CL2023000997A1 (fr) |
| CO (1) | CO2023004365A2 (fr) |
| CR (1) | CR20230159A (fr) |
| DK (1) | DK4225739T3 (fr) |
| DO (1) | DOP2023000069A (fr) |
| EC (1) | ECSP23033936A (fr) |
| FI (1) | FI4225739T3 (fr) |
| HR (1) | HRP20260284T1 (fr) |
| IL (1) | IL301791A (fr) |
| JO (1) | JOP20230072A1 (fr) |
| LT (1) | LT4225739T (fr) |
| MA (1) | MA61866B1 (fr) |
| MX (1) | MX2023003842A (fr) |
| PE (1) | PE20240216A1 (fr) |
| PT (1) | PT4225739T (fr) |
| RS (1) | RS67868B1 (fr) |
| SI (1) | SI4225739T1 (fr) |
| TW (1) | TW202229243A (fr) |
| WO (1) | WO2022076495A1 (fr) |
| ZA (1) | ZA202304148B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202229232A (zh) | 2020-10-08 | 2022-08-01 | 美商默沙東藥廠 | 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之吲哚酮衍生物的製備 |
| IL321166A (en) | 2022-12-02 | 2025-07-01 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US162818A (en) | 1875-05-04 | Improvement in brick-kilns | ||
| WO1998039342A1 (fr) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase |
| ZA981936B (en) | 1997-03-07 | 1999-09-06 | Metabasis Therapeutics Inc | Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase. |
| WO1998039344A1 (fr) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase |
| WO2000014095A1 (fr) | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Nouveaux inhibiteurs heteroaromatiques de fructose-1,6-biphosphatase |
| US6939887B2 (en) | 2001-01-30 | 2005-09-06 | Sumitomo Pharmaceuticals Co., Ltd. | Benzimidazolidinone derivatives |
| WO2003053363A2 (fr) | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| US20080287479A1 (en) | 2006-12-20 | 2008-11-20 | Pfizer Inc | Inhibitors of serine palmitoyltransferase |
| CA2691010A1 (fr) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Pyrimidines fusionnees substituees en tant qu'antagonistes de l'activite de gpr105 |
| EP2174343A1 (fr) | 2007-06-28 | 2010-04-14 | Semiconductor Energy Laboratory Co, Ltd. | Procédé de fabrication d'un dispositif à semi-conducteurs |
| WO2009042053A2 (fr) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Agonistes du récepteur de la neuromédine u et leurs utilisations |
| JP5331883B2 (ja) * | 2009-06-24 | 2013-10-30 | 大日本住友製薬株式会社 | Ｎ−置換−環状アミノ誘導体 |
| SG11201405477XA (en) | 2012-04-06 | 2014-11-27 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors |
| AR098394A1 (es) | 2013-11-25 | 2016-05-26 | Lilly Co Eli | Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2) |
| EP3119757B1 (fr) | 2014-03-17 | 2018-05-16 | Pfizer Inc | Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues |
| US10568876B2 (en) | 2014-09-05 | 2020-02-25 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| US9828369B2 (en) | 2014-09-05 | 2017-11-28 | Merck Sharpe & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| US9877957B2 (en) | 2014-09-05 | 2018-01-30 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| PE20180800A1 (es) | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CA3043206A1 (fr) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | Derives d'indole utiles en tant qu'inhibiteurs de la diacylglyceride o-acyltransferase 2 |
| KR20190078646A (ko) | 2016-11-18 | 2019-07-04 | 머크 샤프 앤드 돔 코포레이션 | 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체 |
| EP3643711A1 (fr) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | Nouveaux composés anthelminthiques |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
-
2021
- 2021-10-06 PT PT218020774T patent/PT4225739T/pt unknown
- 2021-10-06 LT LTEPPCT/US2021/053680T patent/LT4225739T/lt unknown
- 2021-10-06 IL IL301791A patent/IL301791A/en unknown
- 2021-10-06 CR CR20230159A patent/CR20230159A/es unknown
- 2021-10-06 JP JP2023521375A patent/JP7604636B2/ja active Active
- 2021-10-06 CN CN202180082235.8A patent/CN116685577A/zh active Pending
- 2021-10-06 AU AU2021356589A patent/AU2021356589A1/en active Pending
- 2021-10-06 RS RS20260311A patent/RS67868B1/sr unknown
- 2021-10-06 FI FIEP21802077.4T patent/FI4225739T3/fi active
- 2021-10-06 MA MA61866A patent/MA61866B1/fr unknown
- 2021-10-06 KR KR1020237015525A patent/KR20230084258A/ko not_active Ceased
- 2021-10-06 US US17/494,906 patent/US11976061B2/en active Active
- 2021-10-06 CA CA3195014A patent/CA3195014A1/fr active Pending
- 2021-10-06 WO PCT/US2021/053680 patent/WO2022076495A1/fr not_active Ceased
- 2021-10-06 EP EP21802077.4A patent/EP4225739B1/fr active Active
- 2021-10-06 DK DK21802077.4T patent/DK4225739T3/da active
- 2021-10-06 HR HRP20260284TT patent/HRP20260284T1/hr unknown
- 2021-10-06 TW TW110137150A patent/TW202229243A/zh unknown
- 2021-10-06 AR ARP210102766A patent/AR123700A1/es unknown
- 2021-10-06 SI SI202130395T patent/SI4225739T1/sl unknown
- 2021-10-06 PE PE2023001361A patent/PE20240216A1/es unknown
- 2021-10-06 MX MX2023003842A patent/MX2023003842A/es unknown
-
2023
- 2023-04-04 ZA ZA2023/04148A patent/ZA202304148B/en unknown
- 2023-04-05 CL CL2023000997A patent/CL2023000997A1/es unknown
- 2023-04-05 DO DO2023000069A patent/DOP2023000069A/es unknown
- 2023-04-05 CO CONC2023/0004365A patent/CO2023004365A2/es unknown
- 2023-04-06 JO JOJO/P/2023/0072A patent/JOP20230072A1/ar unknown
- 2023-05-08 EC ECSENADI202333936A patent/ECSP23033936A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI4225739T1 (sl) | 2026-03-31 |
| JOP20230072A1 (ar) | 2023-04-06 |
| ZA202304148B (en) | 2024-11-27 |
| US11976061B2 (en) | 2024-05-07 |
| CN116685577A (zh) | 2023-09-01 |
| LT4225739T (lt) | 2026-03-25 |
| JP2023545741A (ja) | 2023-10-31 |
| EP4225739B1 (fr) | 2026-01-21 |
| US20220112182A1 (en) | 2022-04-14 |
| TW202229243A (zh) | 2022-08-01 |
| RS67868B1 (sr) | 2026-04-30 |
| FI4225739T3 (fi) | 2026-03-04 |
| CO2023004365A2 (es) | 2023-04-17 |
| AU2021356589A1 (en) | 2023-05-25 |
| WO2022076495A1 (fr) | 2022-04-14 |
| CL2023000997A1 (es) | 2023-10-06 |
| CA3195014A1 (fr) | 2022-04-14 |
| HRP20260284T1 (hr) | 2026-04-10 |
| IL301791A (en) | 2023-05-01 |
| KR20230084258A (ko) | 2023-06-12 |
| ECSP23033936A (es) | 2023-06-30 |
| JP7604636B2 (ja) | 2024-12-23 |
| DOP2023000069A (es) | 2023-05-15 |
| EP4225739A1 (fr) | 2023-08-16 |
| MX2023003842A (es) | 2023-04-14 |
| CR20230159A (es) | 2023-06-02 |
| AU2021356589A9 (en) | 2025-03-13 |
| PT4225739T (pt) | 2026-04-07 |
| DK4225739T3 (da) | 2026-02-09 |
| AR123700A1 (es) | 2023-01-04 |
| PE20240216A1 (es) | 2024-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU706628B2 (en) | Treatment of arteriosclerosis and xanthoma | |
| FI66860B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-1-imidazolylalkyl)indolderivat | |
| CA3092749A1 (fr) | Composes deuteres utilises en tant qu'inhibiteurs de rock | |
| JPH09505082A (ja) | Ｔｎｆ放出の阻害剤としてのイソオキサゾリン | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| EP2102225A4 (fr) | Dérivés d'alpha-galactosylceramide, sels pharmaceutiquement acceptables de ceux-ci, procédé de préparation et composition pharmaceutique d'adjuvant immunologique contenant ces composés comme principe actif | |
| DOP2023000068A (es) | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| WO2006125180B1 (fr) | Derives de piperazine: utilisation comme agents therapeutiques | |
| AU2007341218B2 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| CO2023004365A2 (es) | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| JPH07228529A (ja) | コリンエステラーゼ賦活剤 | |
| MX2024002146A (es) | Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9. | |
| MA31031B1 (fr) | NOUVEAUX DÉRIVÉS AMINOPYRROLO[1,2-a]INDOLE ET AMINOPYRIDAZINO[1,6-a]INDOLE, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT | |
| GEAP202516792A (en) | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | |
| MX2023007626A (es) | Preparacion de derivados de tetrahidroindazol como innovadores inhibidores de la diacilglicerido o-aciltransferasa 2. | |
| US6156793A (en) | Prophylactic/therapeutic agents for atherosclerosis | |
| WO2023044315A3 (fr) | Inhibiteurs de kca3.1 pour la protection des podocytes | |
| MX2025004975A (es) | Preparación de derivados de triazolopiridina como nuevos inhibidores de diacilglicérido o-aciltransferasa 2 | |
| MX2025004974A (es) | Preparación de derivados de imidazopiridina e imidazopiridazina como inhibidores novedosos de la diacilglicerol u o-aciltransferasa 2 | |
| MX2025004977A (es) | Preparación de derivados de pirazolopiridina y triazolopiridina como inhibidores de diacilglicérido o-aciltransferasa 2 novedosos | |
| US20160355473A1 (en) | Beta-lactam cholesterol absorption inhibitors | |
| KR101902002B1 (ko) | Cetp 억제제로서의 옥사졸리딘온 유도체 화합물 | |
| RU2023131721A (ru) | АГОНИСТ РЕЦЕПТОРОВ THRβ И СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ | |
| MA27408A1 (fr) | Nouveaux composes antimycobacteriens | |
| RU2021120164A (ru) | АГОНИСТ РЕЦЕПТОРОВ THRβ И СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ |